A Phase 3, Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis (PFI) (Also Known as Ledderhose Disease)
Latest Information Update: 23 Oct 2025
At a glance
- Drugs Collagenase clostridium histolyticum (Primary)
- Indications Fibroma
- Focus Registrational; Therapeutic Use
- Acronyms STRIDE
- Sponsors Endo Pharmaceuticals
Most Recent Events
- 20 Oct 2025 Planned End Date changed from 1 Nov 2025 to 1 Mar 2025.
- 20 Oct 2025 Planned primary completion date changed from 1 Nov 2025 to 1 Mar 2026.
- 23 Apr 2024 According to Endo International Media Release, Endo, Inc. a newly formed entity has acquired Endo International plc.